The purpose of the present study is to determine whether ulinastatin, urinary anti-trypsin inhibitor, attenuates cardiopulmonary bypass (CPB)-activated systemic inflammatory response in cardiac surgery with CPB. Serial measurements and analysis of several inflammatory cytokines (bactericidal permeability increasing protein, interleukin-6, tumor necrosis factor-α)as well as markers of cardiac injury, renal impairment and oxygenation profile will be performed to determine ulinastatin's efficacy.
Applying aortic cross-clamp (ACC) and cardiopulmonary bypass (CPB) for cardiac surgery produces variable systemic inflammatory reactions. As a common complication of those reactions, pulmonary dysfunction, which usually indicated by postoperative hypoxemia, is frequently associated with cardiac surgery employing CPB and has been used as a major predictor of morbidity and mortality. Circulating humoral and cellular factors are involved in the development of the systemic inflammatory reactions including organ dysfunction. So far, many studies analyzed the concentration of inflammatory marker (cytokine) to determine the degree of systemic inflammatory responses in various conditions. Ulinastatin has anti-inflammatory activity and suppresses the infiltration of neutrophils. Previous studies suggested ulinastatin's cytoprotective effect against ischemia-reperfusion injury in major organs and its inhibition of inflammatory marker production. The purpose of the present study is to determine ulinastatin's possible protective efficacy of in attenuating CPB-activated systemic inflammatory response regarding postoperative cardiac, renal and pulmonary dysfunction in cardiac surgery with CPB. Serial measurements and analysis of several inflammatory cytokines, such as bactericidal permeability increasing protein (BPI), interleukin (IL)-6, tumor necrosis factor (TNF)-α, as well as markers of cardiac injury, renal impairment and oxygenation profile, such as creatine kinase-MB (CK-MB), troponin I (TnI), C-reactive protein (CRP), arterial O2 tension /inspired O2 fraction (PaO2/FiO2 ratio), will be performed to this purpose.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Enrollment
26
ulinastatin 5000 unit/kg iv before the initiation of CPB
placebo (the same amount of normal saline) iv before the initiation of CPB
Konkuk University Medical Center
Seoul, Seoul, South Korea
bactericidal permeability increasing protein
Time frame: 5-30 min before the end of anesthesia
interleukin-6
Time frame: 5-30 min before the end of anesthesia
tumor necrosis factorTNF-α
Time frame: 5-30 min before the end of anesthesia
Creatine kinase-MB
Time frame: before anesthesia, 24 hour after the end of anesthesia
troponin I
Time frame: before anesthesia, 24 hour after the end of anesthesia
C-reactive protein
Time frame: before anesthesia, 24 hour after the end of anesthesia
serum creatinine
Time frame: before anesthesia, 24 hour after the end of anesthesia
PaO2/FiO2 ratio
Time frame: before anesthesia, 24 hour after the end of anesthesia
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.